A practical reference on c-Met signaling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-13 and is reviewed periodically as new material appears.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
=== Intrinsically disordered proteins === Using a method for the rapid and multiplexed gene synthesis of repetitive polypeptides, Chilkoti created new variants of ELPs that show phase separation. He then built upon these findings to identify new sequence heuristics that enable the de novo design of repetitive polypeptides that show LCST and UCST phase behavior. He postulated that the low sequence complexity, structural disorder, and phase separation behavior of these repetitive polypeptides make them an interesting class of minimal synthetic intrinsically disordered proteins IDPs (synIDPs), and suggested that these SynIDPs can provide insights into the behavior of other more complex, native IDPs. His group has started to exploit the phase transition behavior of two classes of SynIDPs—ELPs that exhibit LCST phase behavior and resilin-like polypeptides (RLPs) that exhibit UCST phase behavior—to create artificial condensates within cells whose material properties and function can be precisely programmed at the sequence level of the SynIDP to reprogram cellular function by spatio-temporally controlling the flow genetic information and biochemical signals within the cell. His later work on functional artificial condensates of SynIDPs in cells includes sequestration of mRNA in a condensate regulate protein translation, sequestration of an enzyme in an artificial condensate to amplify its activity, sequestration of a plasmid to control gene flow in bacteria and recruitment of the transcriptional machinery to amplify gene expression.
== Synthetic biomolecular condensates == Biomolecular condensates can be synthesized for a number of purposes. Synthetic biomolecular condensates are inspired by endogenous biomolecular condensates, such as nucleoli, P bodies, and stress granules, which are essential to normal cellular organization and function. Synthetic condensates are an important tool in synthetic biology, and have a wide and growing range of applications. Engineered synthetic condensates allow for probing cellular organization, regulating cellular physiology, facilitating metabolic pathways, and enable the creation of novel functionalized biological materials, which have the potential to serve as drug delivery platforms and therapeutic agents.
The MEROPS online database for peptidases and their inhibitors: I04.953 Archived 2019-10-16 at the Wayback Machine Angiotensins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human AGT genome location and AGT gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P01019 (Angiotensin) at the PDBe-KB.
are measured in the non-inertial frame. The first term in the parenthesis represents Coriolis acceleration, the second term is due to centrifugal acceleration, the third is due to the linear acceleration of
The type of miso chosen for the soup defines a great deal of its character and flavor. Miso is a Japanese seasoning produced by fermenting soybeans with salt and the fungus Aspergillus oryzae, known in Japanese as kōjikin (麹菌), and sometimes rice, barley, or other ingredients. It can be categorized as red (akamiso), white (shiromiso), or mixed (awase). There are many variations, including regional variations such as Shinshū miso or Sendai miso. The fermentation time affects the flavor: short fermentation, as for white miso, provides a lighter, sweeter flavor, while longer fermentation, as for red miso, gives the miso soup a stronger, deeper flavor. More than 80% of Japan's annual production of miso is used in miso soup, and 75% of all Japanese people consume miso soup at least once a day.
Sources: en.wikipedia.org
. The four approaches deliver slightly different information. Although the results of clamp-, IVGTT-, OGTT- and SPINA-derived disposition indices significantly correlate with each other the correlations are only modest. In direct comparison, the SPINA-based disposition index (SPINA-DI) had higher discriminatory power for the diagnosis of diabetes than the OGTT-based disposition index according to Matsuda and DeFronzo.
=== Dolls === While watching Shinjuuten no Amijima Kaname takes particular notice of the character Koharu, the doll that becomes the ideal of what Kaname thinks women should be (later to be replaced by O-hisa). The conception of womanliness that Koharu inspires in Kaname is what lies at the heart of his Madonna-Harlot conflict, and makes him attracted both to an image of the Virgin Mary and to Hollywood movie stars. He isn’t interested in real women at all, but in idealized forms of them, women who can be appreciated from afar for what they represent not for who they are. Dolls encapsulate this perfectly, being masterfully sculpted, subtle in their beauty, and silently manipulated by men.
=== Embryos === Embryos take 8–12 months to develop due to temperature variations in the environment. The catshark lays eggs in their blastodisc form. The following exhibits a typical developmental timeline (measurements are embryo length):
Proteins that are destined for degradation by the 26S proteasome require two main elements: 1) the attachment of a small protein called ubiquitin and 2) an unstructured region of about 25 amino acids. Proteins that lack this unstructured region can have another motor, cdc48 in yeast or P97 in humans, generate this unstructured region by a unique mechanism where ubiquitin is unfolded by cdc48 and its cofactors Npl4/Ufd1. The tagging of a target protein by ubiquitin is catalyzed by cascade of enzymes consisting of the Ubiquitin-activating enzyme (E1), Ubiquitin-conjugating enzyme (E2), and ubiquitin ligases (E3). Once a protein is tagged with a single ubiquitin molecule, this is a signal to other ligases to attach additional ubiquitin molecules. The result is a polyubiquitin chain that is bound by the proteasome, allowing it to degrade the tagged protein in an ATP dependent manner. The degradation process by the proteasome yields peptides of about seven to eight amino acids long, which can then be further degraded into shorter amino acid sequences and used in synthesizing new proteins.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.